Report Store | Pharma intelligence
  • My Account
    • 0Shopping Cart
  • $0.00
  • Disease analysis
    • Anemias
    • Bacterial infections
    • Bleeding disorders
    • Brain Cancer
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Cerebrovascular diseases
    • Dermatology
    • Diabetes and diabetic complications
    • Gastroenterology
    • Gastrointestinal cancer
    • Head and Neck Cancer
    • Hypertension
    • Immunology and Inflammation
    • Infectious Diseases
    • Ischemic heart disease
    • Leukemia
    • Lung Cancer
    • Lymphoma
    • Oncology overview
    • Market Spotlight
    • Mens Health
    • Neurology
    • Oncology
    • Ophthalmology
    • Other Hematological Cancers
    • Other metabolic diseases
    • Other Solid Cancers
    • Pain
    • Psychiatry
    • Respiratory
    • Rheumatology
    • Skin cancer
    • Thrombosis
    • Urological cancer
    • Vaccines
    • Viral infections
    • Women’s Health
  • Strategy analysis
    • Bleeding disorders
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Commercial Strategy
    • Dealmaking and R&D
    • Head and Neck Cancer
    • Hot Topics
    • Infectious Diseases
    • KOL Insight
    • Leukemia
    • Lung Cancer
    • Manufacturing
    • Market Access
    • Neurology
    • Oncology
    • Outsourcing
    • Pricing & Reimbursement
    • R&D
    • Regulatory & Therapeutic Area
    • Trends
    • Urological cancer
  • Company analysis
    • Big Pharma
    • Emerging Pharma
    • Hot Topics
    • Japan Pharma
    • M&A Analysis
    • Mid Pharma
  • Drug analysis
    • A
    • B-C
    • D-F
    • G-L
    • M-O
    • P-R
    • S-T
    • U-Z
  • MedTech analysis
    • Allergy
    • Autoimmune / Immunology
    • Cardiovascular
    • Dermatology
    • Endocrine
    • ENT / Dental
    • Gastroenterology
    • Hearing
    • Hematology
    • Infectious Diseases
    • Metabolic
    • Neurology
    • Obstetrics / Gynecology
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Osteoporosis
    • Psychiatry
    • Renal
    • Respiratory
    • Rheumatology
    • Urology
  • Opinion & analysis
    • Business Development
    • Business Management
    • Clinical Trials
    • Digital Health
    • Cybersecurity
    • Compliance & Risk
    • Digital patient management
    • Digital policy & regulation
    • Finance & Pricing
    • Healthcare Innovation
    • ICT and Health
    • Leadership
    • Legislation Regulation & Policy
    • Market Access
    • Market Intelligence
    • Medical
    • Pharmaceutical Device
    • Pharmaceutical Research
    • Strategy & Innovation
    • Tech companies & Data
    • Tech & Pharma
  • Blogs
  • Search
  • Menu
You are here: Home > Drug analysis

Drug analysis


  • Sort by Random
    • Default
    • Custom
    • Name
    • Price
    • Date
    • Popularity (sales)
    • Average rating
    • Relevance
    • Random
    • Product ID
  • Display 15 Products per page
    • 15 Products per page
    • 30 Products per page
    • 45 Products per page
  • Byetta

    Read More

    Byetta (exenatide; AstraZeneca) is a member of the glucagon-like peptide-1 (GLP-1) agonist class.

    November 7, 2017
    Find out more
  • MOR208

    Read More

    MorphoSys is positioning its cluster of differentiation (CD)19-targeted monoclonal antibody MOR208 in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients who are ineligible for high-dose chemotherapy and autologous stem cell transplant.

    October 9, 2018
    Find out more
  • pristig report

    Pristiq

    Read More

    Pristiq (desvenlafaxine; Pfizer) is purely a follow-on product to the former leading serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant Effexor (venlafaxine; Pfizer).

    March 29, 2019
    Find out more
  • Enhertu

    Read More

    Enhertu (trastuzumab deruxtecan; Daiichi Sankyo/AstraZeneca) is an antibody-drug conjugate composed of a monoclonal antibody that targets human epidermal growth factor receptor 2 (HER2), an enzymatically cleavable peptide-linker, and a topoisomerase 1 inhibitor derived from exatecan. The drug-to-antibody ratio of Enhertu is 8:1.

    February 26, 2020
    Find out more
  • Gantenerumab

    Read More

    Gantenerumab (Roche/MorphoSys) is a fully humanized centrally and N-acting monoclonal antibody that primarily targets fibrillar amyloid-beta.

    September 2, 2016
    Find out more
  • Glembatumumab Vedotin

    Read More

    Glembatumumab vedotin (Celldex) is an antibody–drug conjugate that targets cancer cells expressing glycoprotein non-metastatic B.

    April 15, 2016
    Find out more
  • Oral Vidaza

    Read More

    Oral Vidaza is an orally available formulation of Vidaza (azacitidine; Celgene/Nippon Shinyaku), a small molecule cytidine nucleoside analog that exerts its anti-cancer activity through direct cytotoxicity as well as through DNA hypomethylation.

    July 6, 2017
    Find out more
  • Votrient

    Read More

    Votrient (pazopanib; Novartis) is an oral angiogenesis inhibitor targeting the vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and c-KIT. Preclinical studies have shown the role of PDGF in modulating angiogenesis

    March 6, 2019
    Find out more
  • Lebrikizumab

    Read More

    Lebrikizumab (Roche/Chugai) is a humanized monoclonal antibody that binds to interleukin (IL)-13. IL-13 induces bronchial epithelial cells to secrete periostin, a matricellular protein.

    May 12, 2016
    Find out more
  • Kinenza

    Read More

    Kinenza (enzastaurin) is an oral serine/threonine kinase inhibitor that suppresses signaling of protein kinase C (PKC)-beta to induce cell apoptosis, reduce cell proliferation, and suppress tumor-induced angiogenesis.

    October 9, 2018
    Find out more
  • Imlygic

    Read More

    Imlygic (talimogene laherparepvec; Amgen) is a gene-deleted oncolytic herpes simplex virus-1 (HSV-1) that encodes human granulocyte-macrophage colony-stimulating factor (GM-CSF). Upon administration, Imlygic replicates selectively in tumor cells and generates GM-CSF.

    May 23, 2018
    Find out more
  • Prevnar 13

    Read More

    Prevnar 13 is Pfizer’s follow-on vaccine to Prevnar 7, which was the first pneumococcal conjugate vaccine licensed in the US.

    December 21, 2018
    Find out more
  • Abraxane

    Read More

    Abraxane (nab-paclitaxel; Bristol-Myers Squibb) is a novel albumin-bound formulation of paclitaxel. Paclitaxel is an insoluble taxane classified as an anti-microtubule agent; it stops the growth of tumors by inhibiting mitosis during metaphase.

    February 26, 2020
    Find out more
  • Copaxone

    Read More

    Copaxone is an immunomodulator composed of four amino acids found in myelin basic protein, believed to act by modifying immune processes in the pathogenesis of MS. It was the third disease-modifying MS drug to be available in the US, following its April 1997 launch.

    November 24, 2017
    Find out more
  • Iomab-B

    Read More

    Iomab-B is a radioimmunotherapy comprised of the monoclonal antibody BC8 coupled with the radioisotope Iodine-131.

    July 6, 2017
    Find out more
Page 5 of 41
Page 5 of 41«‹34567›»
  • Home
  • Terms and Conditions
  • Refund policy
  • Privacy Policy
  • Cookie Policy
  • Contact Us
  • About Us
  • Discounts
  • Market Spotlight – Reports
  • twitter
  • linkedin
  • Sitemap
Copyright © 2022 Pharma Intelligence UK Limited Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London, SW1P 1WG. Pharma Intelligence UK Limited is part of the Pharma Intelligence Group.

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Call Back
Scroll to top